An observational study in Contrast-associated Acute Kidney Injury, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
This is a single-center, prospective observational study. We aim to evaluate the performance of transdermal glomerular filtration rate (TGFR) compared with baseline estimated glomerular filtration rate (eGFR) for early prediction of contrast-associated acute kidney injury (CA-AKI) in emergency patients scheduled for contrast-enhanced CT. Eligible participants are adult emergency patients with baseline eGFR between 15 and 120 mL/min/1.73m². TGFR monitoring will be performed during the peri-contrast CT period. We will collect clinical and laboratory data and follow up renal function after contrast exposure to analyze the predictive value of TGFR for CA-AKI. No extra therapeutic interventions will be applied in this study.
This is a single-center, prospective observational study conducted in the emergency department. Adult patients who require contrast-enhanced computed tomography (CT) examination and have baseline estimated glomerular filtration rate (eGFR) ranging from 15 to 120 mL/min/1.73m² will be consecutively enrolled. Transdermal glomerular filtration rate (TGFR) monitoring will be implemented throughout the peri-contrast CT period. Baseline demographic information, clinical characteristics, laboratory parameters and contrast agent-related data will be collected. Serum creatinine will be tested after contrast exposure to identify cases of contrast-associated acute kidney injury (CA-AKI). The primary objective is to assess the predictive performance of TGFR for CA-AKI compared with conventional baseline eGFR. No study-related therapeutic interventions will be performed. All clinical managements follow routine emergency clinical practice. The total planned sample size is 30 subjects.
Adult patients aged ≥18 years receiving emergency iodinated contrast-enhanced CT scan. We will observe the incidence of contrast-associated acute kidney injury and continuous transdermal renal monitoring.
Exclusion Criteria:
Adult emergency patients scheduled for contrast-enhanced CT. TGFR monitoring will be performed during peri-contrast period. No therapeutic intervention will be applied; all clinical management follows routine practice.
Device: Transdermal glomerular filtration rate (TGFR) monitoring
Non-invasive transdermal glomerular filtration rate measurement performed during peri-contrast period for research observation only. No therapeutic treatment will be delivered. All clinical care remains routine standard care.
Incidence of contrast-associated acute kidney injury (CA-AKI)
Incidence of contrast-associated acute kidney injury within 72 hours after contrast media administration, defined by serum creatinine elevation criteria.
Time frame: Within 72 hours after contrast injection
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Individual participant data (IPD) of this study will not be shared with external researchers, to protect patient privacy and comply with Chinese healthcare data protection regulations.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine